Tag:
SEC
Latest Headlines
Latest Headlines
SEC probes Dendreon amid shareholder lawsuits
The company disclosed the SEC probe in its quarterly filing, along with information about shareholder lawsuits that accuse the company of misleading investors about its prostate cancer therapy Provenge.
Biotech ‘gambler’ Blech loses big in securities scam
The house won again on Wednesday. The one-time "King of Biotech" David Blech has admitted guilt to securities fraud stemming from an elaborate trading scheme to juice the stock prices of two biotech companies.
UPDATED: Baxter bitten again by problems with Colleague infusion pumps
The company says it was served a subpoena in March by the SEC which wants info "related to the company's accounting treatment, financial reporting and disclosures relating to the remediation and recall of the company's Colleague and Syndeo infusion pumps," MassDevice reports.
Baxter gets SEC subpoena on recalled infusion pumps
The SEC wants to see Baxter International's financial records on the recalls of its Colleague and Syndeo infusion pumps back in 2010, which were pulled from shelves by the FDA.
Biomet to cough up almost $23M to settle bribery charges
Another devicemaker has been ensnared in a Foreign Corrupt Practices Act probe.
SEC lays out "tall tales" in $20M biotech securities scam
According to executives at Immunosyn and its controlling shareholder Argyll Biotechnologies, the biotech was onto something truly special. Its lead drug, SF-1019, which had been derived from goat's
Depuy pays $7.9 million to end UK bribe case
Johnson & Johnson's DePuy International unit has agreed to pay about $7.9 million to end a UK probe into whether it paid bribes to Greek officials to win contracts to supply orthopedic products.
Report: Feds scrutinizing Boston Scientific recall
The Justice Department and the SEC are investigating Boston Scientific's recent recall of implantable heart defibrillators, The Wall Street Journal reports, citing an internal company memo. Although
SEC sues CellCyte, former execs for lying to investors
The SEC has filed a lawsuit against Bothell, WA-based CellCyte Genetics and two former executives for lying to investors regarding its stem cell therapies. The developer has already been in hot water
